/SMMT

Summit Therapeutics Inc

SMMT

$17.55USD↑+3.24%+0.55 today

MARKET CAP

14.0B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$17 – $18

52W RANGE

$12

$29

AI Summary

Stalk

StalkMedium

SMMT has triggered a clear momentum breakout and exhibits bullish medium-term structure supported by active continuation patterns. However, price is extended above rising EMAs with extreme overbought readings, warranting patience. A deferred buy on pullbacks into the rising 9/20 EMA zone aligns with speculative strategy discipline and manages risk against the longer-term downtrend.

↑Ibanesimab delivered statistically significant PFS in four Phase III trials.
↑$690.7M cash balance and zero debt fund PDUFA readiness.
↓Approval uncertain without statistically significant overall survival benefit.

Full analysis →

Buying

8

institutions

Selling

3

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	SELL	9.53 M	138.84 M	+-124.72 K	-24.1%	0.00%
PA Point72 Asset Management, L.P. Q2 2026	BUY	3.70 M	53.88 M	+2.90 M	+254.7%	0.06%
CA Citadel Advisors LLC Q2 2026	BUY	2.88 M	41.89 M	+1.81 M	+108.3%	0.00%
MM Millennium Management LLC Q2 2026	BUY	2.35 M	34.23 M	+2.22 M	+1329.6%	0.01%
BA Balyasny Asset Management L.P. Q2 2026	BUY	1.90 M	27.74 M	+1.36 M	+166.9%	0.04%
AC Aqr Capital Management LLC Q2 2026	BUY	542.18 K	7.90 M	+98.42 K	-2.6%	0.00%
WP Woodline Partners LP Q2 2026	SELL	214.51 K	3.13 M	+-214.51 K	-61.6%	0.01%
AC Adar1 Capital Management, LLC Q2 2026	BUY	191.87 K	2.80 M	+100.00 K	+60.5%	0.13%
JC Jpmorgan Chase & Co Q2 2026	BUY	68.17 K	1.07 M	+3.62 K	-2.8%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	BUYNEW	45.16 K	658.04 K	+45.16 K	+0.0%	0.00%
RC Rockefeller Capital Management L.P. Q2 2026	SELL	10.00	146.00	+-27.00	-79.2%	0.00%